| Filed On | Filing |
|---|---|
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
– Q3 2026 Net Revenue of $863 million; GAAP Net Loss of $22 million; Diluted Loss per Share of $(0.06) – |
| 10 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +3 more
THIS FIRST AMENDMENT TO THE THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Amendment”), is entered into as of August 10, 2026 (the “Execution Date”), by and among Amneal Pharmaceuticals, Inc., a Delaware corporation (the “Compa... |
| 03 Aug 2026 |
8-K: Entry into a Material Definitive Agreement
Execution Version 1 4896-6230-8791.1 AMENDMENT NO. 3 TO TERM LOAN CREDIT AGREEMENT AMENDMENT NO. 3 TO TERM LOAN CREDIT AGREEMENT, dated as of August 3, 2026 (this “Amendment”), to the Term Loan Credit Agreement, dated as of November 14, ... |
| 31 Jul 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On July 31, 2026, Amneal Pharmaceuticals, Inc., a Delaware corporation (“Amneal”), held a special meeting of stockholders (the “Special Meeting”) at which holders of Amneal’s Class A common stock, par value $0.01 per share (“Common Stock... |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
– Q2 2026 Net Revenue of $796 million; GAAP Net Income of $58 million; Diluted Income per Share of $0.18 – |
| 07 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Amneal Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on May 6, 2026. Each of the proposals was approved, and each of the director nominees was elected, by the vote of the stockh... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
‒ Q1 2026 Net Revenue of $723 million; GAAP Net Income of $62 million; Diluted Income per Share of $0.19 ‒ |
| 22 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
This Membership Interest Purchase Agreement (this “Agreement”) is made and entered into as of April 21, 2026, by and among Kashiv BioSciences, LLC, a Delaware limited liability company (the “Company”), Amneal Pharmaceuticals, Inc., a Del... |
| 27 Feb 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – |
| 03 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
AMENDMENT NO. 2 TO TERM LOAN CREDIT AGREEMENT, dated as of February 2, 2026 (this “Amendment”), to the Term Loan Credit Agreement, dated as of November 14, 2023 (as amended, restated, supplemented or otherwise modified from time to time ... |
| 28 Jan 2026 |
8-K: Other Events
On January 23, 2026, Amneal Pharmaceuticals, Inc. (the “Company”) determined that it will make effective its nationwide agreement to settle a substantial majority of the opioids-related claims brought against the Company by various state... |
| 13 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
In connection with a presentation to be made at an investor conference on January 13, 2026, Amneal Pharmaceuticals, Inc., a Delaware corporation (“Amneal” or the “Company”), intends to announce that it expects to meet or exceed its 2025 ... |
| 30 Oct 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
‒ Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 ‒ |
| 05 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
‒ Q2 2025 Net Revenue of $725 million; GAAP Net Income of $22 million; Diluted Income per Share of $0.07 ‒ |
| 01 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
This AMENDMENT NO. 2 TO REVOLVING CREDIT AGREEMENT AND AMENDMENT NO. 2 TO COLLATERAL AGREEMENT, dated as of August 1, 2025 (this “Amendment No. 2”), is entered into by and among AMNEAL PHARMACEUTICALS LLC, a Delaware limited liability co... |
| 24 Jul 2025 |
8-K: Other Events
On July 24, 2025, Amneal Pharmaceuticals, Inc. (the “Company”) announced that its subsidiary, Amneal Pharmaceuticals LLC (the “Issuer”), has priced its offering of $600 million aggregate principal amount of 6.875% senior secured notes du... |
| 21 Jul 2025 |
8-K: Other Events
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032 |
| 21 Jul 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more
– Results Reflect Continued Financial Strength and Deleveraging – |
| 08 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Amneal Pharmaceuticals, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) on May 6, 2025. Each of the proposals was approved, and each of the director nominees was elected, by the vote of the stockh... |
| 02 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
‒ Q1 2025 Net Revenue of $695 million; GAAP Net Income of $12 million; Diluted Income per Share of $0.04 ‒ |
Loading...